LAS VEGAS, March 6, 2012 /PRNewswire/ -- Altogen Biosystems announced the launch of its new pancreas-targeted in vivo RNAi transfection system in the company's popular in vivo delivery product line for use in laboratories and research facilities for development of new medicines and testing in cells and animals. This in vivo reagent is designed for targeted siRNA delivery into pancreas, however it is also compatible for transfection of any negatively charged molecules including RNA, DNA, proteins, and small molecules.
The pancreas is very important hormone-secreting organ in the human body. Pancreatic diseases include: Diabetes, pancreatitis, cystic fibrosis, and neoplasms. Pancreatic cancer is the fourth leading cause of cancer death in the United States with a lowest survival rate of its victims than any other form of cancer. Researchers in diabetes, pancreatic cancer, and other pancreas disorders, are focused on discovering and developing new therapeutics for patients. Testing novel compounds require efficient and targeted delivery of pharmaceuticals into pancreas tissue (known as in vivo transfection).
Pancreas-targeted siRNA In Vivo Transfection Kit enables researchers to utilize in vivo transfection method to introduce DNA, RNA, and other molecules into pancreas cells. This liposome-based technology makes it possible to cross the cellular barriers and deliver genetic material, or a small interfering RNA (siRNA) into the cells for research or therapeutic purposes. Highly efficient targeted delivery of biomolecules to pancreas tissue is achieved via multiple administration routes: intravenous, intratumoral, intraperitoneal, or subcutaneous.
About Altogen Biosystems
Altogen Biosystems (www.altogen.com) is a life sciences company located in Las Vegas, Nevada. Altogen Biosystems specializing in the development of pre-optimized in vitro transfection reagents and in vivo delivery systems, transfection products and services. Altogen Labs (www.altogenlabs.com) is a GLP-compliant laboratory contract research organization. The company offers pre-clinical research and biology CRO services including: xenograft animal models (cancer), cryopreservation and cell banking services, generation of stable cell lines, gene silencing RNAi services, tissue-targeted in vivo siRNA and DNA delivery services, custom liposome encapsulation, and cell-based assay development.
Link: Pancreas-targeted siRNA In Vivo Transfection Kit - http://www.altogen.com/Pancreas-In-Vivo-Transfection-Reagent-mouse-rat-tumor-animal-model-sirna-dna-protein-pancreas-invivo-delivery.php
SOURCE Altogen Biosystems